A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands
A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands
复制标题
DOI：
10.1016/j.oraloncology.2005.12.026
复制
发表时间：
2007-01-01
期刊：
影响因子：
4.8
通讯作者：
Levitt, Mark
中科院分区：
文献类型：
--
作者：
Pfeffer, M. Raphael;Talmi, Yoav;Levitt, Mark
涎腺腺样囊性癌的特点是对化疗反应差。大多数腺样囊性癌表达c-kit蛋白。伊马替尼甲磺酸盐（格列卫）抑制几种蛋白酪氨酸激酶，包括c-kit。因此，我们假设伊马替尼可能是治疗局部晚期或转移性腺样囊性癌患者的有效药物，并进行了2期试验以研究这一点。患有局部晚期或转移性腺样囊性癌和c-kit阳性肿瘤的患者符合资格。筛选了14名患者，10名c-kit阳性肿瘤患者（71%）进入研究。以400 mg/天的伊马替尼剂量开始治疗。在无毒性的情况下允许剂量递增。3例患者的剂量增加至600 mg/d，1例患者增加至800 mg/d。3例患者因3级毒性需要将剂量降至300 mg/d。未观察到4级毒性。未观察到客观反应。2例患者（20%）分别表现出11个月和14个月的疾病稳定。所有其他患者在2-14（中位数6）个月后因疾病进展而停止治疗。伊马替尼对晚期头颈部腺样囊性癌没有大的影响。(c)2006爱思唯尔有限公司保留所有权利。
Adenoid cystic carcinoma of the salivary glands is characterized by a poor response to chemotherapy. Most cases of adenoid cystic carcinoma express the c-kit protein. Imatinib mesylate (Gleevec) inhibits several protein-tyrosine kinases, including c-kit. We therefore hypothesized that Imatinib may be an effective drug in patients with locally advanced or metastatic adenoid cystic carcinoma and conducted a phase 2 trial in order to study this. Patients with locally advanced or metastatic adenoid cystic carcinoma and c-kit positive tumours were eligible. Fourteen patients were screened and 10 patients (71%) with c-kit positive tumours entered the study. Treatment was begun at a dose of Imatinib of 400 mg/day. Dose escalation was allowed in the absence of toxicity. The dose was increased to 600 mg/d in three patients and 800 mg/d in one patient. Three patients required dose reduction to 300 mg/d, due to grade 3 toxicity. No grade 4 toxicity was seen. No objective responses were seen. Two patients (20%) exhibited stable disease for 11 and 14 months, respectively. All other patients stopped treatment after 2-14 (median 6) months due to progressive disease. Imatinib has no major effect on advanced adenoid cystic carcinoma of the head and neck. (c) 2006 Elsevier Ltd. All rights reserved.